| abstract |
Dihydrophteridinone derivatives, methods for their preparation and their pharmaceutical uses are described. Specifically, the novel dihydrophthyridinone derivatives represented by the general formula (I) (each substituent of the general formula (I) is as defined in the specification), a preparation method thereof, and a pharmaceutical comprising the derivative Compositions and therapeutic agents, especially their use as Plk kinase inhibitors, are described. |